Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma

Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice

“…This was contrary to the findings of Posch et al who did not find any impact of low prechemotherapy hemoglobin levels in cancer patients on cancer-associated thrombosis. 38 Consistent with the ThroLy results and literature, 19,39 we confirmed the impact of the presence of mediastinum involvement on VTE risk. In our study population, we were unable to show any significance of extranodal localization or the presence of neutropenia (<1 × 10 9 /L) on the VTE risk.…”

Thrombosis and Hemostatic Abnormalities in Hematological Malignancies

“…[5][6][7][8][9][10] The rate of thrombotic complications in lymphoproliferative disease is highly variable, ranging from 1.5% up to 59.5%. This wide variability is mainly because of the different study types (prospective or retrospective, with hospitalized or ambulatory patients), types of disease (indolent vs. aggressive), the disease stage, and different intensities and qualities of the chemotherapeutic protocols.…”

“…The reason for this high incidence might be because of the combination of CNS involvement by tumor-causing hypomobility and the intensive chemotherapy often associated with dexamethasone given to control brain edema. [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] Similarly, nearly all patients developed thromboembolic complications during the first 3 months of therapy, further suggesting the role of chemotherapy in the pathogenesis of VTE.…”

“…[1][2][3][4] Recent studies have shown that the incidence of thrombosis might be as high (or even higher) in patients with malignant hematological disorders, but there is a paucity of data that pertain to patients with hematological malignancies. [5][6][7][8][9][10] Moreover, the patients included in the published case series often differ for the type and the stage of hematological malignancy, the antitumor therapy received, and the use of central venous devices (CVDs), thus making it difficult to draw any meaningful conclusions from the published data. [11][12][13][14][15][16][17] Clinically silent hemostatic abnormalities are found in most patients affected by hematological malignancies but only a limited number of patients show clinical manifestations including VTE, pulmonary embolism (PE), disseminated intravascular coagulopathy (DIC), and life-threatening thrombohemorrhagic syndrome, in which thrombosis and bleeding can occur concomitantly.…”

Thrombose de la veine cave supérieure et lymphome B à grandes cellules du médiastin : 2 cas pédiatriques

“…Dans un tiers des cas elles sont identifiées lors du diagnostic [9]. D'autres études les ont rapportées au cours des 3 premiers mois de traitement ou lors de l'évaluation avant le 3 e cycle de chimiothérapie dans 63 à 87 % des cas [5][6][7][8][9]. Dans les études pédiatriques, les facteurs de risque de thrombose sont un âge > 10 ans [7], une dysfonction du cathéter central (infection ou occlusion) [7] et l'atteinte médiastinale [8].…”